Delivery of therapeutic agents via the pulmonary route has gained significant attention over
the past few decades because this route of administration offers multiple advantages over …

Lung cancer is the leading cause of cancer-related death worldwide, with approximately 1.2
million deaths annually. The standard-of-care in patients with advanced disease is platinum …

Abstract Localized angiopoietin-2 (Ang2) expression has been shown to function as a key
regulator of blood vessel remodeling and tumor angiogenesis, making it an attractive …

Non-small-cell lung cancer (NSCLC) is a leading cause of malignancy-related mortality in
the Western world. Despite advances in early detection and standard treatment, NSCLC is …

Nanotechnology is a field which has been at the forefront of research over the past two
decades. The full potential of nanotechnology has yet to be fully realized. One subset of …

The controversial roles of mesenchymal stem cells (MSCs) in lung cancer development are
not yet resolved because of the lack of an extracellular environment that mimics the tumor …

Non-small cell lung cancer can be classified into several histologic subtypes, most
commonly lung adenocarcinoma (LADC) or squamous cell carcinoma (SqCC). With the …

The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has
witnessed a swift evolution. The number of targeted drugs that can improve patient …

In recent years, a number of new agents that target specific molecular pathways in non-small
cell lung cancer (NSCLC) have been investigated. Much effort has been focused on …

Site-specific drug delivery and targeting attracts much research interest from both academia
and industry, but because of the many challenges faced in the development of these …